A recent analysis in 127 patients with metastatic HER2 positive BC receiving trastuzumab-based treatment revealed a significantly shorter time to first metastasis in tumors exhibiting low- and high-level ERBB2/ CEP17 ratios [27], an outcome that seemed more prominent when absolute ERBB2 copy numbers were >13. This evidence concerns the gene ERBB2 and breast cancer.